Association of the Affordable Care Act’s Medicaid Expansion with the diagnosis and treatment of clinically localized melanoma: A National Cancer Database Study

Abstract Background The Affordable Care Act’s Medicaid expansion is associated with earlier diagnosis and improved care among lower socioeconomic status populations with cancer, but its impact on melanoma is undefined. Objective To determine the association of Medicaid expansion with stage of diagnosis and utilization of sentinel lymph node biopsy (SLNB) in non-elderly adult patients with newly diagnosed clinically localized melanoma. Methods Quasi-experimental, difference-in-differences retrospective cohort analysis using data from the National Cancer Database from 2010 to 2017. Patients from expansion versus non-expansion states and diagnosed before (2010-13) versus after (2014-17) expansion were identified. Results Of 83,322 patients, 46.6% were female, and the median age was 55 (interquartile range 49-60) years. Following risk adjustment, Medicaid expansion was associated with a decrease in the diagnosis of ≥T1b stage melanoma (odds ratio [OR] 0.93, 95% confidence interval [CI] 0.88-0.98, P=0.011) and decrease in uninsured status (OR 0.61, 95% CI 0.52-0.72, P Limitations Retrospective study using a national database. Conclusion In this study of patients with clinically localized melanoma, Medicaid expansion was associated with a decrease in the diagnosis of later T-stage tumors.